SuperworthRepligen free cash flow RGEN
Cash from operations less capital spending, by quarter and over the last twelve months, from 2010.
- Last 12 months, to Jun 30, 2026
- $112M
- Latest quarter, Q2 FY26
- $27.4M
- +28% on a year earlier
- Fiscal year 2025
- $93.9M
- −37% on the year before
Repligen's free cash flow was $112M over the twelve months to Jun 30, 2026, up 3% on a year earlier.
In its latest quarter, Q2 FY26, it was $27.4M, up 28% on the same quarter a year before.
Over the five fiscal years to FY2025 it grew 19% a year on average.
Free cash flow over time
Fiscal year by fiscal year
| Fiscal year | Free cash flow | Change |
|---|---|---|
| FY2025 | $93.9M | −37% |
| FY2024 | $149.7M | +93% |
| FY2023 | $77.7M | −11% |
| FY2022 | $87.2M | +68% |
| FY2021 | $51.9M | +29% |
| FY2020 | $40.2M | −18% |
| FY2019 | $48.7M | +133% |
| FY2018 | $20.9M | +74% |
| FY2017 | $12M | +275% |
| FY2016 | $3.2M | −74% |
| FY2015 | $12.4M | −3% |
| FY2014 | $12.8M | −39% |
| FY2013 | $20.9M | +72% |
| FY2012 | $12.2M | +310% |
| FY2011 | $3M | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Free cash flow | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $27.4M | +28% | $112M | |
| Q1 FY26 | $23.6M | +106% | $106M | |
| Q4 FY25 | $17.6M | −48% | $93.9M | |
| Q3 FY25 | $43.4M | +3% | $110M | |
| Q2 FY25 | $21.5M | −42% | $108.9M | |
| Q1 FY25 | $11.4M | −69% | $124.8M | |
| Q4 FY24 | $33.6M | +87% | $149.7M | |
| Q3 FY24 | $42.3M | +37% | $134.1M | |
| Q2 FY24 | $37.4M | +43% | $122.6M | |
| Q1 FY24 | $36.4M | +1275% | $111.4M | |
| Q4 FY23 | $18M | −57% | $77.7M | |
| Q3 FY23 | $30.8M | +4% | $101.2M |
Against its peers
Companies in Biotechnology nearest Repligen's size, closest first, today.
| Company | Free cash flow yield |
|---|---|
| RGENRepligen | 1.1% |
| KRYSKrystal Biotech | 2.8% |
| TECHBIO-TECHNE | 2.3% |
| HALOHalozyme Therapeutics | 5.7% |
| NBIXNeurocrine Biosciences | 6.0% |
| EXELExelixis | 7.3% |
| INCYIncyte | 8.2% |
| UTHRUnited Therapeutics | 4.3% |
| ALNYAlnylam Pharmaceuticals | 2.6% |
| ADMAAdma Biologics | 4.9% |
| ONCBeOne Medicines | 3.1% |
| Peer median | 4.6% |
Where Repligen ranks
What the free cash flow tells you
Cash from operations minus capital spending. The cash the company could hand back or reinvest.
Seasonal and lumpy quarter to quarter. The TTM view is the one to trust.
More on Repligen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.